153 related articles for article (PubMed ID: 29714832)
1. Successful Therapy with Nivolumab in Metastatic Renal Cell Carcinoma After Multiple Prior Treatments.
Finelli NC; Baig SA; Masters GA
Del Med J; 2017 Jan; 89(1):14-17. PubMed ID: 29714832
[TBL] [Abstract][Full Text] [Related]
2. Nivolumab in the treatment of advanced renal cell carcinoma.
Arasaratnam M; Gurney H
Future Oncol; 2018 Jul; 14(17):1679-1689. PubMed ID: 29460635
[TBL] [Abstract][Full Text] [Related]
3. The option value of innovative treatments for non-small cell lung cancer and renal cell carcinoma.
Thornton Snider J; Batt K; Wu Y; Tebeka MG; Seabury S
Am J Manag Care; 2017 Oct; 23(10):e340-e346. PubMed ID: 29087638
[TBL] [Abstract][Full Text] [Related]
4. Anti-programmed Cell Death Protein 1 (PD-1) Antibody Nivolumab Leads to a Dramatic and Rapid Response in Papillary Renal Cell Carcinoma with Sarcomatoid and Rhabdoid Features.
Geynisman DM
Eur Urol; 2015 Nov; 68(5):912-4. PubMed ID: 26194044
[No Abstract] [Full Text] [Related]
5. The safety and efficacy of nivolumab for the treatment of advanced renal cell carcinoma.
Ornstein MC; Rini BI
Expert Rev Anticancer Ther; 2016 Jun; 16(6):577-84. PubMed ID: 27144724
[TBL] [Abstract][Full Text] [Related]
6. Significant response to nivolumab for metastatic chromophobe renal cell carcinoma with sarcomatoid differentiation: a case report.
Noguchi G; Tsutsumi S; Yasui M; Ohtake S; Umemoto S; Nakaigawa N; Yao M; Kishida T
BMC Urol; 2018 Apr; 18(1):26. PubMed ID: 29669553
[TBL] [Abstract][Full Text] [Related]
7. Case of complete response to neoadjuvant therapy using nivolumab in a patient with metastatic renal cell carcinoma.
Ikarashi D; Kato Y; Katagiri H; Takahara T; Uesugi N; Shiomi E; Sugimura J; Nitta H; Sugai T; Obara W
Int J Urol; 2018 Jun; 25(6):630-632. PubMed ID: 29693280
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics, pharmacodynamics and clinical efficacy of nivolumab in the treatment of metastatic renal cell carcinoma.
Farolfi A; Schepisi G; Conteduca V; Burgio SL; Lolli C; De Giorgi U
Expert Opin Drug Metab Toxicol; 2016 Sep; 12(9):1089-96. PubMed ID: 27450183
[TBL] [Abstract][Full Text] [Related]
9. [Metastatic renal cell carcinoma, back to the future].
Martins F; Berthold D
Rev Med Suisse; 2016 May; 12(519):994-8. PubMed ID: 27424427
[TBL] [Abstract][Full Text] [Related]
10. An evaluation of nivolumab for the treatment of metastatic renal cell carcinoma.
Zarrabi K; Wu S
Expert Opin Biol Ther; 2018 Jun; 18(6):695-705. PubMed ID: 29782188
[TBL] [Abstract][Full Text] [Related]
11. Negative prognostic factors and resulting clinical outcome in patients with metastatic renal cell carcinoma included in the Italian nivolumab-expanded access program.
Bracarda S; Galli L; Maruzzo M; Lo Re G; Buti S; Favaretto A; Di Costanzo F; Sacco C; Merlano M; Mucciarini C; Zafarana E; Romito S; Maestri A; Giorgio CG; Ionta MT; Turci D; De Giorgi U; Procopio G; Cortesi E; Giannarelli D; Porta C
Future Oncol; 2018 Jun; 14(14):1347-1354. PubMed ID: 29774766
[TBL] [Abstract][Full Text] [Related]
12. [Initial Clinical Experience of Nivolumab for Metastatic Renal Cell Carcinoma].
Fukunaga A; Yamasaki T; Okuno T; Imai K; Ikeuchi R; Hishiki K; Goto T; Sawada A; Negoro H; Akamatsu S; Saito R; Kobayashi T; Inoue T; Ogawa O
Hinyokika Kiyo; 2018 Oct; 64(10):383-389. PubMed ID: 30543735
[TBL] [Abstract][Full Text] [Related]
13. Pushing the limits of immune-related response: a case of "extreme pseudoprogression".
Wong AS; Thian YL; Kapur J; Leong CN; Kee P; Lee CT; Lee MB
Cancer Immunol Immunother; 2018 Jul; 67(7):1105-1111. PubMed ID: 29728723
[TBL] [Abstract][Full Text] [Related]
14. Emerging monoclonal antibodies for the treatment of renal cell carcinoma (RCC).
Atkins MB; Philips GK
Expert Opin Emerg Drugs; 2016 Sep; 21(3):243-54. PubMed ID: 27539246
[TBL] [Abstract][Full Text] [Related]
15. Impressive and durable response to nivolumab in a patient with metastatic type 2 papillary renal cell carcinoma: On-label but without evidence.
Adrianzen Herrera DA; Fleisig SB; Gartrell BA
Invest New Drugs; 2017 Oct; 35(5):665-668. PubMed ID: 28466375
[TBL] [Abstract][Full Text] [Related]
16. Kidney metastases.
Dresler CM
Chest Surg Clin N Am; 1998 Feb; 8(1):127-9. PubMed ID: 9515177
[TBL] [Abstract][Full Text] [Related]
17. Safety and activity of sorafenib in different histotypes of advanced renal cell carcinoma.
Procopio G; Verzoni E; Gevorgyan A; Mancin M; Pusceddu S; Catena L; Platania M; Guadalupi V; Martinetti A; Bajetta E
Oncology; 2007; 73(3-4):204-9. PubMed ID: 18418013
[TBL] [Abstract][Full Text] [Related]
18. Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib.
Zimmermann K; Schmittel A; Steiner U; Asemissen AM; Knoedler M; Thiel E; Miller K; Keilholz U
Oncology; 2009; 76(5):350-4. PubMed ID: 19321976
[TBL] [Abstract][Full Text] [Related]
19. [Clinical observation of 21 cases of metastatic renal cell carcinoma treated with sorafenib].
Xie XD; Piao Y; Liu ZZ
Zhonghua Zhong Liu Za Zhi; 2009 Sep; 31(9):714-5. PubMed ID: 20021872
[No Abstract] [Full Text] [Related]
20. Targeted Therapy for Renal Cell Carcinoma.
Joshi R; Rawal S
JNMA J Nepal Med Assoc; 2015; 53(198):83-8. PubMed ID: 26994026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]